PHOSPHOLINE IODIDE
LOE Approachingechothiophate iodide for ophthalmic solution
NDAOPHTHALMICFOR SOLUTION
Approved
Jun 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Drug Shortage Active
PHOSPHOLINE IODIDE is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
PHOSPHOLINE IODIDE (echothiophate iodide for ophthalmic solution) is clinical pharmacology echothiophate iodide for ophthalmic solution is a long-acting cholinesterase inhibitor for topical use which enhances the effect of endogenously liberated acetylcholine in iris, ciliary muscle, and other parasympathetically innervated structures of the eye. Approved for elevated iop. First approved in 1960.
Drug data last refreshed 10h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Phospholine Iodide (echothiophate iodide) is a long-acting cholinesterase inhibitor ophthalmic solution approved in 1960 for treating elevated intraocular pressure. It works by enhancing acetylcholine effects in the eye to promote miosis, increase aqueous humor outflow, and lower IOP. The drug is indicated for glaucoma and ocular hypertension management.
$0.942MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D activity signals a small, declining team focused on legacy support rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Echothiophate iodide for ophthalmic solution is a long-acting cholinesterase inhibitor for topical use which enhances the effect of endogenously liberated acetylcholine in iris, ciliary muscle, and other parasympathetically innervated structures of the eye. It thereby causes…
Indications (1)
Career Relevance
Phospholine Iodide is linked to zero active job openings, signaling minimal commercial infrastructure or team expansion. Working on this product offers little upward mobility or cross-functional opportunity typical of growing franchises.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.